MCID: BRY005
MIFTS: 40

Beryllium Disease

Categories: Immune diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Beryllium Disease

MalaCards integrated aliases for Beryllium Disease:

Name: Beryllium Disease 52 71
Subacute Berylliosis 52 71
Acute Berylliosis 52 71
Chronic Pulmonary Berylliosis 52
Reversible Berylliosis 52
Beryllliosis 52

Classifications:



External Ids:

UMLS 71 C0221053 C0340178 C2350873

Summaries for Beryllium Disease

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 133 Definition A pneumoconiosis, characterized by granulomatous inflammation, that occurs in individuals who develop beryllium sensitization (BeS), a cell -mediated immune response to environmental and occupational beryllium exposure. BeS precedes the lung disease that may present with chronic dry cough, fatigue, weight loss, chest pain, and increasing dyspnea. Epidemiology The number of workers exposed to beryllium has been estimated at 1 million in the US, although no accurate figure exists for the US or globally. The prevalence of BeS in those exposed ranges from 1 - 20%. Chronic beryllium disease (CBD) among those with BeS ranges from 15-100%. Clinical description Patients with CBD can range from those who are asymptomatic to those with severe lung dysfunction. Manifestations occur a few months to many years after exposure to beryllium and include chronic dry cough, dyspnea on exertion, chest pain, fatigue, fever, night sweats and weight loss. Additional extrapulmonary manifestations of dermatitis and skin granulomas have been reported. Progressive pulmonary fibrosis can eventually lead to cor pulmonale and respiratory failure. An increased risk of lung cancer among workers exposed to high levels of beryllium has also been observed. Etiology CBD is caused by occupational or environmental exposure to beryllium and beryllium-containing alloys (usually by inhalation of dust or fumes but also via contact with skin). Over time, in a subset of individuals, a cell-mediated immune response to beryllium may occur, causing the development of sensitized T cells that accumulate within the lungs and eventually form granulomas which can lead to fibrosis. A genetic variant in the HLA-DPB1 gene (6p21.3) with the presence of a glutamic acid at amino acid position 69 has been associated with the development of BeS and CBD. Diagnostic methods Diagnosis is based on a history of exposure to beryllium, characteristic clinical findings and laboratory testing. BeS can be detected with the beryllium lymphocyte proliferation test (BeLPT). Chest x-ray , CT scan of the lungs, exercise tolerance testing and pulmonary function tests can also aid in the diagnosis. Sampling of the lung with for example bronchoscopy with biopsy and bronchoalveolar lavage is usually required to demonstrate granulomatous inflammation in the lungs and or sensitization to beryllium Differential diagnosis The main differential diagnoses are sarcoidosis (most common), hypersensitivity pneumonitis and tuberculosis as well as other occupational lung diseases (such as silicosis). Management and treatment There is no cure for CBD. Treatment involves recommendations for cessation of beryllium exposure as medically prudent, and the use of immunosuppressive therapies, such as corticosteroids (prednisone ). Early symptomatic disease may be treated with inhaled corticosteroids along with a short acting bronchodilator. Methotrexate and other immunosuppressive therapies can reduce steroid side effects. The efficacy of corticosteroids may be limited and relapses can occur after cessation of therapy or when dose is lowered. Those with advanced disease and major breathing difficulties may require oxygen supplementation. In severe cases, a lung transplant may be suggested. Patients should refrain from smoking. CBD may be prevented by providing exposed workers with respiratory protective devices and protective clothing and by minimizing exposure through use of workplace administration and engineering controls. The BeLPT is used to identify patients early on and to define workplace areas for modification in order to ultimately reduce additional BeS and CBD cases. Prognosis Prognosis varies, with some patients remaining clinically stable for many years and some experiencing a gradual worsening of symptoms over time. A debilitating course resulting in respiratory failure is also possible but regular monitoring and treatment can slow down the disease process. Visit the Orphanet disease page for more resources.

MalaCards based summary : Beryllium Disease, also known as subacute berylliosis, is related to chronic beryllium disease and berylliosis. An important gene associated with Beryllium Disease is HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Infliximab and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells.

Wikipedia : 74 Berylliosis, or chronic beryllium disease (CBD), is a chronic allergic-type lung response and chronic... more...

Related Diseases for Beryllium Disease

Diseases in the Beryllium Disease family:

Chronic Beryllium Disease

Diseases related to Beryllium Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 chronic beryllium disease 32.2 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-DPA1
2 berylliosis 31.7 HLA-DRB1 HLA-DPB1 HLA-DPA1
3 sarcoidosis 1 30.5 TNF HLA-DRB1 HLA-DQB1
4 autoimmune disease 29.1 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1
5 inflammatory bowel disease 27.8 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
6 lung disease 10.7
7 allergic hypersensitivity disease 10.3
8 pulmonary sarcoidosis 10.2
9 idiopathic interstitial pneumonia 10.2
10 pulmonary fibrosis 10.2
11 neonatal lupus erythematosus 10.1 HLA-DQA1 HLA-DPB1
12 limbic encephalitis with lgi1 antibodies 10.1 HLA-DRB1 HLA-DQB1
13 autoimmune polyglandular syndrome type 3 10.1 HLA-DRB1 HLA-DQB1
14 pulmonary hypertension 10.1
15 bronchiectasis 10.1
16 achalasia, familial esophageal 10.1 HLA-DQB1 HLA-DQA1
17 myelitis 10.1 TNF HLA-DPB1
18 hypersomnia 10.1 HLA-DRB1 HLA-DQB1
19 narcolepsy 2 10.1 HLA-DRB1 HLA-DQB1
20 type ii mixed cryoglobulinemia 10.1 HLA-DRB1 HLA-DQB1
21 moyamoya angiopathy 10.1 HLA-DRB1 HLA-DQB1
22 recurrent respiratory papillomatosis 10.1 HLA-DRB1 HLA-DQB1
23 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
24 pneumoconiosis 10.1
25 anthracosis 10.1
26 pneumothorax 10.1
27 interstitial lung disease 10.1
28 metal allergy 10.1 HLA-DRB1 HLA-DQB1
29 pediatric multiple sclerosis 10.1 HLA-DRB1 HLA-DQB1
30 podoconiosis 10.1 HLA-DQB1 HLA-DQA1
31 osteonecrosis of the jaw 10.1 HLA-DRB1 HLA-DQB1
32 narcolepsy 1 10.1 HLA-DRB1 HLA-DQB1
33 red cell aplasia 10.1 HLA-DRB1 HLA-DQB1
34 pityriasis rosea 10.1 HLA-DRB1 HLA-DQB1
35 whipple disease 10.1 HLA-DRB1 HLA-DQB1
36 ocular cicatricial pemphigoid 10.1 HLA-DRB1 HLA-DQB1
37 cicatricial pemphigoid 10.1 HLA-DRB1 HLA-DQB1
38 congenital toxoplasmosis 10.0 HLA-DQB1 HLA-DQA1
39 paraneoplastic pemphigus 10.0 HLA-DRB1 HLA-DQB1
40 pure red-cell aplasia 10.0 HLA-DRB1 HLA-DQB1
41 cystic echinococcosis 10.0 HLA-DRB1 HLA-DQB1
42 echinococcosis 10.0 TNF HLA-DRB1
43 acute chest syndrome 10.0 HLA-DRB1 HLA-DQB1
44 eosinophilia-myalgia syndrome 10.0 HLA-DRB1 HLA-DQA1
45 peanut allergy 10.0 HLA-DRB1 HLA-DQB1
46 cryoglobulinemia 10.0 TNF HLA-DRB1
47 microscopic polyangiitis 10.0 TNF HLA-DRB1
48 cardiac sarcoidosis 10.0 TNF HLA-DQB1
49 neuromyelitis optica 10.0 HLA-DRB1 HLA-DPB1
50 nontuberculous mycobacterial lung disease 10.0 TNF HLA-DRB1

Graphical network of the top 20 diseases related to Beryllium Disease:



Diseases related to Beryllium Disease

Symptoms & Phenotypes for Beryllium Disease

Drugs & Therapeutics for Beryllium Disease

Drugs for Beryllium Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 1, Phase 2 170277-31-3
2 Anti-Inflammatory Agents Phase 1, Phase 2
3 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
4 Analgesics, Non-Narcotic Phase 1, Phase 2
5 Mesalamine Phase 1, Phase 2 89-57-6
6 Analgesics Phase 1, Phase 2
7 Antirheumatic Agents Phase 1, Phase 2
8 Gastrointestinal Agents Phase 1, Phase 2
9 Dermatologic Agents Phase 1, Phase 2
10
Heparin Approved, Investigational 9005-49-6 772 46507594
11
Acetylcysteine Approved, Investigational 616-91-1 12035
12
Cysteine Approved, Nutraceutical 52-90-4 5862
13 Pharmaceutical Solutions
14 calcium heparin
15 Anti-Infective Agents
16 Respiratory System Agents
17 Free Radical Scavengers
18 Antiviral Agents
19 Antioxidants
20 N-monoacetylcystine
21 Protective Agents
22 Antidotes
23 Expectorants

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Targeting Oxidative Stress in Chronic Beryllium Disease Completed NCT01088243 Phase 1, Phase 2 Mesalamine;Placebo
2 Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial Terminated NCT00111917 Phase 1, Phase 2 Infliximab
3 The Role of JAK2 in Alveolar Macrophages in Chronic Beryllium Disease Unknown status NCT02596347
4 Shared Genetic Susceptibility in CBD and Sarcoidosis Completed NCT00560989
5 The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis Completed NCT01587001 Placebo
6 Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Recruiting NCT02604693

Search NIH Clinical Center for Beryllium Disease

Genetic Tests for Beryllium Disease

Anatomical Context for Beryllium Disease

MalaCards organs/tissues related to Beryllium Disease:

40
Lung, Testes, T Cells, Skin, Monocytes, Heart, Kidney

Publications for Beryllium Disease

Articles related to Beryllium Disease:

(show top 50) (show all 444)
# Title Authors PMID Year
1
Lack of an Exposure Response and Interaction With HLA-DPβ1 and DRβ1 Polymorphisms in the Development of Beryllium Toxicity in a High Beryllium Exposure Cohort. 61
31743304 2020
2
Molecular mechanism of Be2+-ion binding to HLA-DP2: tetrahedral coordination, conformational changes and multi-ion binding. 61
31833509 2020
3
Associations of Metrics of Peak Inhalation Exposure and Skin Exposure Indices With Beryllium Sensitization at a Beryllium Manufacturing Facility. 61
31504146 2019
4
Polymorphism of FCGR3A gene in chronic beryllium disease. 61
30245507 2019
5
New insight in beryllium toxicity excluding exposure to beryllium-containing dust: accumulation patterns, target organs, and elimination. 61
30891623 2019
6
Occupational exposure to beryllium in French industries. 61
30570429 2019
7
Interstitial Lung Diseases in Developing Countries. 61
30741505 2019
8
DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease. 61
30141971 2019
9
TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization. 61
30185516 2018
10
Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT). 61
29574954 2018
11
[Differential Diagnosis of Mediastinal and Hilar Lymphadenopathy with Focus on Occupational Diseases]. 61
29046010 2018
12
Effect of inhaled corticosteroids on lung function in chronic beryllium disease. 61
29453139 2018
13
Immunologic Effects of Beryllium Exposure. 61
29676647 2018
14
5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects. 61
29080069 2018
15
Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. 61
29066387 2018
16
Interstitial pneumonia in a glassblower: think to chronic beryllium disease! 61
31011396 2018
17
High-Affinity Interactions of Beryllium(2+) with Phosphatidylserine Result in a Cross-Linking Effect Reducing Surface Recognition of the Lipid. 61
28872302 2017
18
Clinical tool for disease phenotyping in granulomatous lung disease. 61
29145499 2017
19
Occupational Exposure to Beryllium. Final rule. 61
28071878 2017
20
A mortality study of beryllium workers. 61
27766788 2016
21
Chronic Beryllium Disease: The Search for a Dose-Response. 61
27820771 2016
22
Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease. 61
27414009 2016
23
Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis. 61
27103383 2016
24
Beryllium disease and sarcoidosis: still besties after all these years? 61
27246078 2016
25
CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge. 61
26673671 2016
26
Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice. 61
26129650 2016
27
Elemental analysis of occupational granulomatous lung disease by electron probe microanalyzer with wavelength dispersive spectrometer: Two case reports. 61
27330955 2016
28
Identification of metal sensitization in sarcoid-like metal-exposed patients by the MELISA® lymphocyte proliferation test - a pilot study. 61
27076838 2016
29
[A experiment research of beryllium oxide induced oxidative lung injury and the protective effects of LBP in rats]. 61
26653647 2015
30
Gene-environment interaction from international cohorts: impact on development and evolution of occupational and environmental lung and airway disease. 61
26024343 2015
31
Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway. 61
24932923 2015
32
Beryllium and other metal-induced lung disease. 61
25602804 2015
33
Genetic susceptibility to beryllium: a case-referent study of men and women of working age with sarcoidosis or other chronic lung disease. 61
25305207 2015
34
Beryllium increases the CD14(dim)CD16+ subset in the lung of chronic beryllium disease. 61
25689051 2015
35
The beryllium bronchoalveolar lavage lymphocyte proliferation test: indicator of beryllium sensitization, inflammation or both? 61
25942054 2015
36
p38 Mitogen-Activated Protein Kinase in beryllium-induced dendritic cell activation. 61
25454621 2014
37
An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. 61
25398119 2014
38
Illness absences among beryllium sensitized workers. 61
25211750 2014
39
Quantification and micron-scale imaging of spatial distribution of trace beryllium in shrapnel fragments and metallurgic samples with correlative fluorescence detection method and secondary ion mass spectrometry (SIMS). 61
25146877 2014
40
Beryllium BioBank: 2. Lymphocyte proliferation testing. 61
25099413 2014
41
Beryllium Biobank 3: considerations for improving chronic beryllium disease screening. 61
25099414 2014
42
Exposure factors associated with chronic beryllium disease development in Beryllium BioBank participants. 61
25099412 2014
43
Unsuspected exposure to beryllium: potential implications for sarcoidosis diagnoses. 61
25078645 2014
44
Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. 61
24995984 2014
45
Sarcoidosis and chronic beryllium disease: similarities and differences. 61
25007084 2014
46
Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease. 61
24912188 2014
47
Identification of multiple public TCR repertoires in chronic beryllium disease. 61
24719461 2014
48
Chronic Beryllium Disease: revealing the role of beryllium ion and small peptides binding to HLA-DP2. 61
25369028 2014
49
T cell recognition of beryllium. 61
23978481 2013
50
Beryllium disease among construction trade workers at Department of Energy nuclear sites. 61
23794247 2013

Variations for Beryllium Disease

Expression for Beryllium Disease

Search GEO for disease gene expression data for Beryllium Disease.

Pathways for Beryllium Disease

Pathways related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
2
Show member pathways
13.52 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
3
Show member pathways
13.21 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
4
Show member pathways
13.19 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
5
Show member pathways
13 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
6
Show member pathways
12.79 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
7
Show member pathways
12.76 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
8
Show member pathways
12.74 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
9
Show member pathways
12.72 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
10 12.72 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
11
Show member pathways
12.53 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
12
Show member pathways
12.49 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
13
Show member pathways
12.45 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
14
Show member pathways
12.33 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
15
Show member pathways
12.29 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
16
Show member pathways
12.21 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
17 12.19 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
18 12.12 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
19 12.08 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
20
Show member pathways
12.08 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
21 11.99 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
22
Show member pathways
11.91 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
23 11.9 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
24 11.87 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
25 11.78 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
26 11.74 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
27
Show member pathways
11.51 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
28 11.43 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
29 11.11 TNF HLA-DRB1
30 11.07 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

GO Terms for Beryllium Disease

Cellular components related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.04 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
2 plasma membrane GO:0005886 10.02 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
3 endoplasmic reticulum GO:0005783 9.88 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
4 Golgi membrane GO:0000139 9.88 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
5 Golgi apparatus GO:0005794 9.86 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
6 lysosomal membrane GO:0005765 9.85 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
7 endoplasmic reticulum membrane GO:0005789 9.84 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
8 endosome GO:0005768 9.83 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
9 endosome membrane GO:0010008 9.83 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
10 cell surface GO:0009986 9.81 TNF HLA-DRB1 HLA-DPB1 HLA-DPA1
11 lysosome GO:0005764 9.8 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
12 trans-Golgi network membrane GO:0032588 9.8 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
13 endocytic vesicle membrane GO:0030666 9.77 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
14 ER to Golgi transport vesicle membrane GO:0012507 9.72 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
15 transport vesicle membrane GO:0030658 9.65 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
16 clathrin-coated endocytic vesicle membrane GO:0030669 9.55 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
17 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
18 MHC class II protein complex GO:0042613 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

Biological processes related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.8 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
2 immune response GO:0006955 9.8 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
3 adaptive immune response GO:0002250 9.78 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
4 T cell receptor signaling pathway GO:0050852 9.77 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
5 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.65 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
6 positive regulation of interferon-gamma production GO:0032729 9.61 TNF HLA-DPB1 HLA-DPA1
7 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
8 positive regulation of T cell proliferation GO:0042102 9.52 HLA-DPB1 HLA-DPA1
9 positive regulation of T cell activation GO:0050870 9.51 HLA-DPB1 HLA-DPA1
10 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.49 HLA-DRB1 HLA-DQB1
11 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.46 HLA-DRB1 HLA-DQB1
12 antigen processing and presentation GO:0019882 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

Molecular functions related to Beryllium Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
2 peptide antigen binding GO:0042605 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

Sources for Beryllium Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....